Portola receives $89m to begin Betrixaban Phase 3 study
Betrixaban, an oral small molecule, inhibits the activity of Factor Xa, which is pivotal in the blood coagulation pathway. The company intends to begin a Phase 3 betrixaban
Evogene and ELEO have entered a scientific collaboration aimed at discovering and developing new oral small-molecule inhibitors targeting the Proprotein convertase subtilisin/kexin type 9 (PCSK9) pathway for hyperlipidemia and cardiovascular diseases.
Flucytosine Capsules are the generic version of Valeant Pharmaceuticals’ Ancobon Capsules and 500 mg strength of Chloroquine Phosphate Tablets, an approved generic version of Sanofi Aventis’ Aralen Tablets.